PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin-Reference-Cited by-同舟云学术

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

Published:2018-09-07 Issue:10 Volume:7 Page:647-659
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Hanke Nina¹,Frechen Sebastian²,Moj Daniel¹,Britz Hannah¹,Eissing Thomas²,Wendl Thomas²,Lehr Thorsten¹

Affiliation:

1. Clinical Pharmacy; Saarland University; Saarbrücken Germany

2. Clinical Pharmacometrics; Bayer AG; Leverkusen Germany

Funder

Bayer

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/psp4.12343/fullpdf

Reference50 articles.

1. Cytochrome P-450 3A4: regulation and role in drug metabolism;Guengerich;Annu. Rev. Pharmacol. Toxicol.,1999

2. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug;Fenner;Clin. Pharmacol. Ther.,2009

3. U.S. Food and Drug Administration Drug development and drug interactions: table of substrates, inhibitors and inducers https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug–Drug Interaction Between Voriconazole and Flucloxacillin;European Journal of Drug Metabolism and Pharmacokinetics;2024-09-14

2. Physiologically based pharmacokinetic model of brivaracetam to predict the exposure and dose exploration in hepatic impairment and elderly populations;Journal of Pharmaceutical Sciences;2024-09

3. Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling;The Journal of Clinical Pharmacology;2024-08-06

4. An open‐label study to explore the optimal design of CYP3A drug–drug interaction clinical trials in healthy Chinese people;Pharmacology Research & Perspectives;2024-07-28

5. Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic;Drug Metabolism Reviews;2024-07-26